Loading
A phase 2 trial of nivolumab, pemetrexed, gemcitabine, cisplatin and other drugs in lung cancer, run by University Health Network, Toronto, now recruiting.
Using ctDNA to Determine Therapies for Lung Cancer is a phase 2, randomised interventional study registered as NCT04966663 by University Health Network, Toronto, with a registry enrolment figure of 66 participants, started 2022-03-28 and due to reach its primary completion in 2026-08-01. Interventions recorded: Nivolumab; Pemetrexed; Gemcitabine; Cisplatin; Carboplatin; ctDNA blood test. Conditions listed: Non Small Cell Lung Cancer; Complete Surgical Resection; Circulating Tumor DNA. Primary outcome: Relapse Free Survival. Lung eligibility wording from the registry: "Complete surgical resection of T1-2N0M0 NSCLC or T3/T4 multifocal NSCLC". Sites: Canada. No results are recorded here; the registry entry is the source.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cisplatin, Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Gemcitabine, Cisplatin and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cisplatin, Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cisplatin, Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cisplatin, Platinum agents and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Platinum agents, Carboplatin and the tag lung-deep-dive.
Shares Pemetrexed, Lung cancer trials open today (registry snapshot), Cisplatin, Platinum agents and the tag lung-deep-dive.